Transfus Med Rev 1994; 8(1):1–14.56 56. Ching EP, Poon M‐C, Neurath D, Ruether BA. Red blood cell alloimmunization complicating plasma transfusion. Am J Clin Pathol 1991; 96(2):201–202.
57 57. Churchill WH, Schmidt B, Lindsey J, et al. Thawing fresh frozen plasma in a microwave oven: a comparison with thawing in a 37 °C waterbath. Am J Clin Pathol 1992; 97(2):227–232.
58 58. Thompson KS, O’Kell RT. Comparison of fresh‐frozen plasmas thawed in a microwave oven and in a 37°C water bath. Am J Clin Pathol 1981; 75(6):851–853.
59 59. Scott E, Puca K, Heraly J, et al. Evaluation and comparison of coagulation factor activity in fresh‐frozen plasma and 24‐hour plasma at thaw and after 120 hours of 1 to 6°C storage. Transfusion 2009; 49(8):1584–1591.
60 60. Allen CJ, Shariatmadar S, Meizoso JP, et al. Liquid plasma use during “super” massive transfusion protocol. J Surg Res 2015; 199(2):622–628.
61 61. Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009; 23(3):177–188.
62 62. Pool JG, Shannon AE. Production of high‐potency concentrates of antihemophilic globulin in a closed‐bag system. N Engl J Med 1965; 273(27):1443–1447.
63 63. Ness PM. Cryoprecipitate as a reliable source of fibrinogen replacement. JAMA J Am Med Assoc 1979; 241(16):1690.
64 64. Gunson HH. Variables involved in cryoprecipitate production and their effect on factor VIII activity. Br J Haematol 1979; 43(2):287–295.
65 65. Yazer MH, Stapor D, Triulzi DJ. Use of the RQI test for bacterial screening of whole blood platelets. Am J Clin Pathol 2010; 133(4):564–568.
66 66. Sawant RB, Marathe AN. Pooled platelet product using the Acrodose plus system: evaluation of feasibility, safety and efficacy. Transfus Apher Sci 2013; 49(3):535–538.
67 67. Tobian AAR, Fuller AK, Uglik K, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion. 2014; 54(6):1523–1529.
68 68. Kacker S, Ness PM, Savage WJ, et al. The cost‐effectiveness of platelet additive solution to prevent allergic transfusion reactions. Transfusion 2013; 53(11):2609–2618.
69 69. Alhumaidan H, Sweeney J. Current status of additive solutions for platelets. J Clin Apher 2012; 27(2):93–98.
70 70. Murphy S, Heaton W, Rebulla P. Platelet production in the Old World—and the New. Transfusion 1996; 36(8):751–754.
71 71. Schrezenmeier H, Seifried E. Buffy‐coat‐derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; 99(1):1–15.
72 72. Slichter SJ, Harker LA. Preparation and storage of platelet concentrates: II. Storage variables influencing platelet viability and function. Br J Haematol 1976; 34(3):403–419.
73 73. Mourad N. Studies on release of certain enzymes from human platelets. Transfusion 1968; 8(6):363–367.
74 74. Murphy S. Platelets from pooled buffy coats: an update. Transfusion 2005; 45(4):634–639.
75 75. Fijnheer R, Pietersz RNI, De Korte D, et al. Platelet activation during preparation of platelet concentrates: a comparison of the platelet‐rich plasma and the buffy coat methods. Transfusion 1990; 30(7):634–638.
76 76. Eriksson L, Hogman C. Platelet concentrates in an additive solution prepared from pooled buffy coats. I. In vitro studies. Vox Sang 1990; 59:140–145.
77 77. Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability—deleterious effect of refrigerated storage. N Engl J Med 1969; 280(20):1094–1098.
78 78. Murphy S, Sayar SN, Gardner FH. Storage of platelet concentrates at 22 degrees C. Blood 1970; 35:549–557.
79 79. Handin RI, Valeri CR. Hemostatic effectiveness of platelets stored at 22°C. N Engl J Med 1971; 285(10):538–543.
80 80. Filip DJ, Aster RH. Relative hemostatic effectiveness of human platelets stored at 4° and 22°C. J Lab Clin Med 1978; 91:618–624.
81 81. Kunicki TJ, Tuccelli M, Becker GA, Aster RH. A study of variables affecting the quality of platelets stored at “room temperature.” Transfusion 2003; 15(5):414–421.
82 82. Scott E, Slichter S. Viability and function of platelet concentrates stored in CPD‐adenine (CPDA‐1). Transfusion 1980; 20(5):489–497.
83 83. Holme S, Vaidja K, Murphy S. Platelet storage at 22°C: effect of type of agitation on morphology, viability, and function in vitro. Blood 1978; 34:403–419.
84 84. Vassallo RR, Wagner SJ, Einarson M, et al. Maintenance of in vitro properties of leukoreduced whole blood‐derived pooled platelets after a 24‐hour interruption of agitation. Transfusion 2009; 49(10):2131–2135.
85 85. Murphy S, Kahn RA, Holme S, et al. Improved storage of platelets for transfusion in a new container. Blood 1982; 60:194–200.
86 86. Simon T, Nelson E, Murphy S. Extension of platelet concentrate storage to 7 days in second‐generation bags. Transfusion 1987; 27(1):6–9.
87 87. Heal J, Singal S, Sardisco E, Mayer T. Bacterial proliferation in platelet concentrates. Transfusion 1986; 26(4):388–390.
88 88. Braine H, Kickler T, Charache P, et al. Bacterial sepsis secondary to platelet transfusion: an adverse effect of extended storage at room temperature. Transfusion 1986; 26(4):391–393.
89 89. U.S. Deparment of Health and Human Services. Biologics guidances. 2019. Available from: https://ww.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/bacterial‐risk‐control‐strategies‐blood‐collection‐establishments‐and‐transfusion‐services‐enh.
90 90. Simon T, Sierra E. Concentration of platelet units into small volumes. Transfusion 1984; 24(2):173–175.
91 91. Moroff G, Friedman A, Robkin‐Kline L, et al. Reduction of the volume of stored platelet concentrates for use in neonatal patients. Transfusion 1984; 24(2):144–146.
92 92. Strauss RG. Current issues in neonatal transfusions. Vox Sang 1986; 51(1):1–9.
93 93. Eastlund T. Monetary blood donation incentives and the risk of transfusion‐ transmitted infection. Transfusion 1998; 38(9):874–882.
94 94. Walsh JH. Posttransfusion hepatitis after open‐heart operations. JAMA 1970; 211(2):261.
95 95. Prince A. Sterilisation of hepatitis and HTLV‐III viruses by exposure to tri(n‐butyl)phosphate and sodium cholate. Lancet 1986; 327(8483):706–710.
96 96. Dichtelmuller H, Biesert L, Fabrizzi R. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics association member companies. Transfusion 2009; 49:1931–1943.
97 97. Foster PR, Welch AG, McLean C, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox
